Scientific Advisory Board
Brian Fiske
Drug Development
“Great entrepreneurs are known for finishing companies, not starting them”
Brian Fiske is serial entrepreneur, venture creation pioneer, & therapeutics expert with a specialty in oncology.
Started his career at Bain & Company where he worked with with pharmaceutical, hedge fund, and industrial clients.
Brian then joined Flagship Ventures, where he helped co-founded Ohana and KSQ Therapeutics, recruited 25+ FTEs and consultants including C-level and SAB, successfully led two R&D teams to milestones simultaneously, and raised $34M in seed, Series A, and debt financings from Flagship, Polaris Partners, and a venture debt fund. In 2016, he was nationally recognized for healthcare entrepreneurship by Forbes 30 under 30.
In July 2017, he co-founded Mythic Therapeutics, a product-platform company that is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Mythic’s technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. Prior to Mythic, he was a co-founder and Chief Technology Officer at Ohana Biosciences, where he led a team of 10 and was responsible for several biologics programs at the intersection of reproductive medicine and rare disease.
Outside of work you can find Brian running around outside and starting impromptu dance parties with his two daughters Clara (age 4) and Kira (age 2). As for hobbies, Brian tries to sneak a workout in when he can. Take care of yourselves founders, its a long journey, make sure your health & loved ones are a priority!
Brian holds an A.B. summa cum laude in Biochemical Sciences with a secondary field in Economics from Harvard University. While at Harvard, Brian swam for the Men’s Swimming and Diving team and was co-captain his senior year. He later completed his PhD in Biology in Matt Vander Heiden’s lab at MIT where he published over 10 papers in the field of cancer metabolism. He also worked closely with Agios Pharmaceuticals (NASDAQ: AGIO) on their cancer metabolism programs, which have since translated into 4 clinical programs including two approved drugs.
